Treat to Target in Axial Spondyloarthritis: What Are the Issues?

被引：17

作者：

Danve, Abhijeet ^{[1
]}

Deodhar, Atul ^{[2
]}

机构：

[1] Yale Univ, Div Rheumatol, Sch Med, New Haven, CT 06519 USA

[2] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA

来源：

CURRENT RHEUMATOLOGY REPORTS | 2017年 / 19卷 / 05期

关键词：

Ankylosing spondylitis; Axial spondyloarthritis; Remission; Treat to target; PLACEBO-CONTROLLED TRIAL; DISEASE-ACTIVITY SCORE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVE ANKYLOSING-SPONDYLITIS; QUALITY-OF-LIFE; RHEUMATOID-ARTHRITIS; RADIOGRAPHIC PROGRESSION; PSORIATIC-ARTHRITIS; TIGHT CONTROL; OPEN-LABEL;

D O I：

10.1007/s11926-017-0648-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of the review Treat to Target (T2T) strategy has been widely used in the management of chronic medical conditions, such as hypertension, diabetes, and hypothyroidism, as well as rheumatic diseases, such as rheumatoid arthritis and gout. The purpose of this review is to discuss the importance, feasibility, and challenges in adopting the T2T strategy for the management of axial spondyloarthritis (axSpA). Recent findings In 2014, a panel of international experts published recommendations for T2T in axSpA. Recent Tight Control of Inflammation in Early Psoriatic Arthritis (TICOPA) trial demonstrated efficacy of T2T in the management of the psoriatic arthritis. However, there are several issues in the adoption of T2T in axSpA. They include lack of evidence of the impact of aggressive management on clinical and radiographic outcomes in axSpA and unavailability of a definite target for the treatment, as well as limited therapeutic options. In this review, we discuss the intricacies of the T2T strategy in axSpA. Summary We need more clinical evidence in the form of randomized clinical studies to assess the impact of T2T on outcomes in axSpA. We also need a definite target which is useful in the routine clinical practice, as well as for clinical trials.

引用

页数：8

共 63 条

[1]

Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO

[2]

2-F

[3] Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis [J].

Baeten, Dominique ;

Sieper, Joachim ;

Braun, Juergen ;

Baraliakos, Xenofon ;

Dougados, Maxime ;

Emery, Paul ;

Deodhar, Atul ;

Porter, Brian ;

Martin, Ruvie ;

Andersson, Mats ;

Mpofu, Shephard ;

Richards, Hanno B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (26) :2534-2548

[4] Increased mortality in ankylosing spondylitis is related to disease activity [J].

Bakland, Gunnstein ;

Gran, Jan Tore ;

Nossent, Johannes C. .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (11) :1921-1925

[5] Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis [J].

Baraliakos, Xenofon ;

Haibel, Hildrun ;

Listing, Joachim ;

Sieper, Joachim ;

Braun, Juergen .

ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (04) :710-715

[6] Clinical and Imaging Efficacy of Infliximab in HLA-B27-Positive Patients With Magnetic Resonance Imaging-Determined Early Sacroiliitis [J].

Barkham, Nick ;

Keen, Helen I. ;

Coates, Laura C. ;

O'Connor, Philip ;

Hensor, Elizabeth ;

Fraser, Alexander D. ;

Cawkwell, Lorna S. ;

Bennett, Alexander ;

McGonagle, Dennis ;

Emery, Paul .

ARTHRITIS AND RHEUMATISM, 2009, 60 (04) :946-954

[7] Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials [J].

Bhala, N. ;

Emberson, J. ;

Merhi, A. ;

Abramson, S. ;

Arber, N. ;

Baron, J. A. ;

Bombardier, C. ;

Cannon, C. ;

Farkouh, M. E. ;

FitzGerald, G. A. ;

Goss, P. ;

Halls, H. ;

Hawk, E. ;

Hawkey, C. ;

Hennekens, C. ;

Hochberg, M. ;

Holland, L. E. ;

Kearney, P. M. ;

Laine, L. ;

Lanas, A. ;

Lance, P. ;

Laupacis, A. ;

Oates, J. ;

Patrono, C. ;

Schnitzer, T. J. ;

Solomon, S. ;

Tugwell, P. ;

Wilson, K. ;

Wittes, J. ;

Baigent, C. ;

Adelowo, O. ;

Aisen, P. ;

Al-Quorain, A. ;

Altman, R. ;

Bakris, G. ;

Baumgartner, H. ;

Bresee, C. ;

Carducci, M. ;

Chang, D-M. ;

Chou, C-T. ;

Clegg, D. ;

Cudkowicz, M. ;

Doody, L. ;

El Miedany, Y. ;

Falandry, C. ;

Farley, J. ;

Ford, L. ;

GarciLosa, M. ;

Gonzalez-Ortiz, M. ;

Haghighi, M. .

LANCET, 2013, 382 (9894) :769-779

[8] Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients [J].

Boonen, A ;

Chorus, A ;

Miedema, H ;

van der Heijde, D ;

van der Tempel, H ;

van der Linden, S .

ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (04) :353-358

[9] 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis [J].

Braun, J. ;

van den Berg, R. ;

Baraliakos, X. ;

Boehm, H. ;

Burgos-Vargas, R. ;

Collantes-Estevez, E. ;

Dagfinrud, H. ;

Dijkmans, B. ;

Dougados, M. ;

Emery, P. ;

Geher, P. ;

Hammoudeh, M. ;

Inman, R. D. ;

Jongkees, M. ;

Khan, M. A. ;

Kiltz, U. ;

Kvien, T. K. ;

Leirisalo-Repo, M. ;

Maksymowych, W. P. ;

Olivieri, I. ;

Pavelka, K. ;

Sieper, J. ;

Stanislawska-Biernat, E. ;

Wendling, D. ;

Ozgocmen, S. ;

van Drogen, C. ;

van Royen, B. J. ;

van der Heijde, D. .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :896-904

[10]

Braun J, 1998, ARTHRITIS RHEUM-US, V41, P58, DOI 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.3.CO

← 1 2 3 4 5 6 7 →